MedTrace Logo

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

NCT06806982 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-08-28

No results posted yet for this study

Summary

This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.

Conditions

  • HER2-positive Solid Tumors

Interventions

DRUG

VRN101099

Oral capsules

Sponsors & Collaborators

  • Voronoi, Inc

    lead INDUSTRY

Principal Investigators

  • Daekwon Kim · Voronoi, Inc. Chief Executive Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2026-05-01
Completion
2027-07-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06806982 on ClinicalTrials.gov